UpdatesPress Release
Supriya Lifescience's Q1 FY27 revenue surged 30.8% YoY to 189.75 Cr, though PAT decreased to 24.04 Cr.
Supriya Lifescience LimitedSUPRIYA · Filed with the exchange
Key growth drivers include strong export focus, new product commercialization in Anesthetic/ADHD segments, and commissioning of its Ambernath finished dosage facility.
No comments yet. Be the first.